ReviewAnnals of translational medicine2016
Biomarkers of risk to develop lung cancer in the new screening era.
Review in Annals of translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Predictive performance of risk prediction models for lung cancer incidence in Western and Asian countries: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Biomarker Detection of Lung Cancers Before Clinical Symptoms or the Use of Traditional Imaging Methods in the ITALUNG Trial.International journal of molecular sciences · 2026Trial
- The Role of Biomarkers in Lung Cancer Screening.Cancers · 2024Review
- What Can Current Biomarker Data Tell Us About the Risks of Lung Cancer Posed by Heated Tobacco Products?Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2024Article
- Combining Low-Dose Computer-Tomography-Based Radiomics and Serum Metabolomics for Diagnosis of Malignant Nodules in Participants of Lung Cancer Screening Studies.Biomolecules · 2023Article
- Biomarkers in Lung Cancer Screening: a Narrative Review.Current challenges in thoracic surgery · 2023Article
- Lung function impairment in lung cancer screening: discordance between risk and screening outcomes when looking through a PRISm.Translational lung cancer research · 2022Article
- The Lipid Composition of Serum-Derived Small Extracellular Vesicles in Participants of a Lung Cancer Screening Study.Cancers · 2021Article
- A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer.Translational research : the journal of laboratory and clinical medicine · 2021Article
- Serum Metabolite Profiles in Participants of Lung Cancer Screening Study; Comparison of Two Independent Cohorts.Cancers · 2021Article
- Review
- Hybrid models for lung nodule malignancy prediction utilizing convolutional neural network ensembles and clinical data.Journal of medical imaging (Bellingham, Wash.) · 2020Article
- Delta radiomic features improve prediction for lung cancer incidence: A nested case-control analysis of the National Lung Screening Trial.Cancer medicine · 2018Article
- The narrow path to organized LDCT lung cancer screening programs in Europe.Journal of thoracic disease · 2018Review
- Fluctuating Behavior of the French Population in Cancer Screening: 5th Edition of the EDIFICE Survey.Current oncology reports · 2018Observational
- A robust gene expression-based prognostic risk score predicts overall survival of lung adenocarcinoma patients.Oncotarget · 2018Article
- The prognostic value of neutrophil to lymphocyte and platelet to lymphocyte ratios for patients with lung cancer.Oncology letters · 2017Article
- Sputum-based DNA methylation biomarkers to guide lung cancer screening decisions.Journal of thoracic disease · 2017Article
- Proteomic analysis of bronchoalveolar lavage fluid (BALF) from lung cancer patients using label-free mass spectrometry.BBA clinical · 2017Article
- Circulating and tissue biomarkers in early-stage non-small cell lung cancer.Ecancermedicalscience · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Low-dose computed tomography for high-risk individuals has for the first time demonstrated unequivocally that early detection save lives. The currently accepted screening strategy comes at the cost of a high rate of false positive findings while still missing a large percentage of the cases. Therefore, there is increasing interest in developing strategies to better estimate the risk of an individual to develop lung cancer, to increase the sensitivity of the screening process, to reduce screening costs and to reduce the numbers of individuals harmed by screening and follow-up interventions. New molecular biomarkers candidates show promise to improve lung cancer outcomes. This review discusses the current state of biomarker research in lung cancer screening with the primary focus on risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.